Inhibition cAMP-phosphodiesterase in the rat heart by pentoxifylline--a new xanthine derivative
Related Experiment Video
Updated: Oct 27, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Abstract:
Pentoxifylline, a new xanthine derivative with properties favorably affecting the rheological profile of blood, was administered to male rats weighing 200--300 g in doses of 5, 10, 15, and 20 mg/kg of body weight for five days. Up to 27% of the intracellular cAMP-phosphodiesterase (cAMP-PDE) of the myocardium was dose-dependently inhibited. A significant increase in the protein content of the heart (wet weight) was also recorded, but was unrelated to the dose of pentoxifylline and without evidence of cardiac hypertrophy.
More Related Videos
08:39Single-Cell Optical Action Potential Measurement in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: December 22, 2020
14:39Cholinergic Ligand–dependent Modulation of Oxidative Phosphorylation Coupling in Digitonin-permeabilized BE(2)-C Neuroblastoma Cells
Published on: April 28, 2026
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...